Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 13Spondylitis, Ankylosing 4Psoriasis 4Colitis, Ulcerative 3Uveal Melanoma 1Spondylarthritis 1Recurrence 1Plaque Psoriasis 1Osteoarthritis 1Nephrotic Syndrome 1Nephrosis, Lipoid 1Mucopolysaccharidosis VI 1Mucopolysaccharidosis II 1Mucopolysaccharidosis I 1Mucopolysaccharidoses 1Melanoma 1Macular dystrophy, corneal type 1 1Kidney Diseases 1Joint Diseases 1Inflammatory Bowel Diseases 1Inflammation 1Hidradenitis Suppurativa 1Healthy 1Glomerulosclerosis, Focal Segmental 1Dupuytren Contracture 1Crohn Disease 1Arthritis, Psoriatic 1Arthritis 1Acne Vulgaris 1Abscess 1

Interventions

Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mucopolysaccharidosis II × Adalimumab × Clear all
NCT02437253 2017-09-15

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
2 enrolled 10 charts

Inflammation, Mucopolysaccharidosis I, Mucopolysaccharidoses, Mucopolysaccharidosis VI, Mucopolysaccharidosis II

Data powered by HemOnc (CC BY 4.0) Colophon âš¡